Surrozen, Inc. (NASDAQ:SRZN) Given Consensus Rating of “Moderate Buy” by Analysts

Surrozen, Inc. (NASDAQ:SRZN) has been assigned a consensus rating of “Moderate Buy” from the six brokerages that are presently covering the firm, MarketBeat reports. Two equities research analysts have rated the stock with a sell recommendation, three have given a buy recommendation and one has issued a strong buy recommendation on the company. The average 1 year price target among brokerages that have issued a report on the stock in the last year is $42.00.

A number of research firms have recently commented on SRZN. HC Wainwright reaffirmed a “buy” rating and set a $44.00 target price (up from $36.00) on shares of Surrozen in a research note on Thursday, May 7th. Cantor Fitzgerald restated an “overweight” rating and set a $40.00 price objective on shares of Surrozen in a report on Tuesday, March 24th. Zacks Research downgraded Surrozen from a “hold” rating to a “strong sell” rating in a research report on Monday, June 29th. TD Cowen began coverage on Surrozen in a research note on Tuesday, April 21st. They issued a “buy” rating on the stock. Finally, Wall Street Zen upgraded Surrozen from a “sell” rating to a “hold” rating in a research report on Saturday, March 28th.

Insider Transactions at Surrozen

In related news, VP Yang Li sold 1,584 shares of the firm’s stock in a transaction dated Monday, May 4th. The shares were sold at an average price of $33.33, for a total value of $52,794.72. Following the transaction, the vice president owned 17,216 shares of the company’s stock, valued at $573,809.28. This trade represents a 8.43% decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, COO Charles O. Williams sold 2,036 shares of Surrozen stock in a transaction dated Monday, May 4th. The shares were sold at an average price of $33.33, for a total transaction of $67,859.88. Following the sale, the chief operating officer owned 16,571 shares of the company’s stock, valued at $552,311.43. The trade was a 10.94% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Over the last ninety days, insiders have sold 8,144 shares of company stock worth $271,440. Insiders own 31.74% of the company’s stock.

Institutional Trading of Surrozen

Large investors have recently modified their holdings of the company. Empery Asset Management LP purchased a new position in Surrozen during the 4th quarter worth $2,350,000. 5AM Venture Management LLC increased its stake in shares of Surrozen by 25.0% during the fourth quarter. 5AM Venture Management LLC now owns 387,500 shares of the company’s stock valued at $8,758,000 after buying an additional 77,500 shares during the period. Spruce Street Capital LP bought a new stake in shares of Surrozen in the fourth quarter valued at about $9,764,000. 683 Capital Management LLC purchased a new stake in Surrozen in the fourth quarter worth about $949,000. Finally, Eversept Partners LP grew its holdings in Surrozen by 23.8% during the 4th quarter. Eversept Partners LP now owns 95,286 shares of the company’s stock worth $2,153,000 after acquiring an additional 18,289 shares in the last quarter. Hedge funds and other institutional investors own 66.57% of the company’s stock.

Surrozen Stock Performance

SRZN stock opened at $24.92 on Friday. The stock has a market cap of $289.32 million, a PE ratio of -0.66 and a beta of 0.51. Surrozen has a 12 month low of $8.00 and a 12 month high of $35.00. The company has a 50-day moving average price of $26.39 and a 200 day moving average price of $25.23.

Surrozen (NASDAQ:SRZN) last posted its quarterly earnings data on Wednesday, May 6th. The company reported ($11.65) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.09) by ($10.56). The company had revenue of $5.00 million for the quarter, compared to the consensus estimate of $4.00 million. Sell-side analysts forecast that Surrozen will post -7.2 EPS for the current year.

Surrozen Company Profile

Surrozen, Inc is a clinical-stage biopharmaceutical company focused on developing novel therapeutic antibodies that target the Wnt signaling pathway for applications in tissue repair, regeneration and oncology. Founded in 2012 and headquartered in South San Francisco, California, the company leverages its proprietary SurroBody platform to design bispecific antibody molecules capable of modulating Wnt receptor activity with enhanced tissue specificity.

The SurroBody platform enables the generation of high-affinity, dual-binding antibodies engineered to either activate or inhibit Wnt signaling, a pathway critical to cell proliferation, differentiation and homeostasis.